Amlodipine: Uses, Dosing, Side Effects, and How It Compares to Statins

What Is Amlodipine and How Does It Work?

Amlodipine blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac tissue, reducing intracellular calcium influx, relaxing arterial walls, and lowering peripheral vascular resistance. Blood pressure falls within hours of the first dose. The drug's unusually long half-life of 30 to 50 hours smooths out peaks and troughs, reducing the reflex tachycardia common with shorter-acting calcium channel blockers.

The FDA first approved amlodipine (brand name Norvasc, Pfizer) in 1992 for hypertension and angina. Generic amlodipine has been widely available since 2007 and today costs under $15 per month at most pharmacies, making it one of the most cost-accessible antihypertensives on the market.

Because amlodipine acts primarily on peripheral arterioles rather than on the cardiac conduction system, it is preferred over non-dihydropyridine CCBs (verapamil, diltiazem) when physicians want blood pressure control without slowing heart rate. JNC 8 guidelines list thiazides, CCBs, ACE inhibitors, and ARBs as first-line antihypertensives, placing amlodipine squarely in the preferred first-line category for most adult patients.

A 2003 meta-analysis of 29 randomized trials (N = 74,696) published in the Lancet confirmed that CCBs produce equivalent reductions in coronary heart disease events compared with diuretics and beta-blockers at equivalent blood-pressure reductions, supporting their broad use in guideline-concordant practice. See the BPLTTC meta-analysis on the Lancet.

FDA-Approved Indications and Off-Label Uses

Amlodipine carries three FDA-approved indications. First, hypertension in adults and pediatric patients aged 6 to 17. Second, chronic stable angina. Third, vasospastic (Prinzmetal) angina. The FDA prescribing information specifies that amlodipine may be used alone or in combination with other antihypertensive and antianginal agents.

Off-label, physicians sometimes prescribe amlodipine for Raynaud's phenomenon. A 2014 Cochrane systematic review found that CCBs reduced the frequency of Raynaud's attacks by approximately 2.8 to 5 attacks per week compared with placebo. Read the Cochrane review here.

In pediatric hypertension, amlodipine 2.5 to 5 mg daily is supported by the 2017 American Academy of Pediatrics guideline for children aged 6 and older with confirmed hypertension. The AAP guideline is available via the NIH.

Dosing and Administration

The standard starting dose for adults is 5 mg orally once daily. Patients with hepatic impairment or elderly patients may start at 2.5 mg once daily because hepatic metabolism via CYP3A4 is reduced in those populations, raising plasma concentrations. The dose may be titrated upward to 10 mg once daily after 7 to 14 days if blood pressure or angina remains inadequately controlled.

No dose adjustment is required for renal impairment. Because the half-life ranges from 30 to 50 hours, steady-state plasma concentrations are reached after 7 to 8 days of once-daily dosing. PubMed pharmacokinetic data confirm these values.

Taking amlodipine with or without food does not meaningfully affect absorption. Peak plasma concentration occurs 6 to 12 hours post-dose. Bioavailability is approximately 64 to 90%, and the volume of distribution is roughly 21 L/kg, indicating extensive tissue binding.

The 2018 ACC/AHA guideline on the management of blood cholesterol recommends targeting systolic blood pressure below 130 mmHg in adults with atherosclerotic cardiovascular disease. Access the guideline at the AHA Journals. Amlodipine 10 mg produces average systolic reductions of 12 to 15 mmHg in clinical trials, making it a workable single-agent approach for stage 1 hypertension.

Key Clinical Trial Evidence

The ASCOT-BPLA trial (Anglo-Scandinavian Cardiac Outcomes Trial, N = 19,257) is the most cited evidence base for amlodipine in high-risk hypertensive patients. Patients randomized to an amlodipine-based regimen (with perindopril added if needed) experienced a 23% relative risk reduction in fatal and nonfatal stroke versus an atenolol-based regimen (hazard ratio 0.77 to 95% CI 0.66 to 0.89, P<0.0003). The trial was stopped early at a median 5.5 years because of the clear mortality benefit in the amlodipine arm. Read ASCOT-BPLA in The Lancet.

The ACCOMPLISH trial (N = 11,506) compared amlodipine plus benazepril with hydrochlorothiazide plus benazepril in high-risk hypertensives. The amlodipine combination reduced the primary composite of cardiovascular death, nonfatal MI, and nonfatal stroke by 19.6% (HR 0.80 to 95% CI 0.72 to 0.90, P<0.001). ACCOMPLISH was published in the New England Journal of Medicine.

The ALLHAT trial (N = 33,357) compared chlorthalidone, amlodipine, and lisinopril in patients with hypertension and at least one CHD risk factor. Amlodipine and lisinopril were equivalent to chlorthalidone for the primary composite endpoint of fatal CHD and nonfatal MI, confirming CCBs as first-line alternatives to thiazide diuretics. ALLHAT is published in JAMA.

The three trials together form a consistent picture: amlodipine-based therapy reduces stroke and major cardiovascular events at least as well as older beta-blocker and diuretic-based regimens, and outperforms atenolol-based strategies in stroke prevention. Physicians at HealthRX use this evidence to prioritize amlodipine in patients with hypertension plus high stroke risk, particularly those who already carry a statin prescription for concurrent dyslipidemia.

Side Effects and Safety Profile

Peripheral edema is the most common dose-dependent side effect of amlodipine, occurring in roughly 10.8% of patients at 10 mg vs. 1.8% at 2.5 mg in pooled clinical trial data cited in the FDA prescribing label. The FDA label data are available here. The edema results from pre-capillary arteriolar dilation rather than fluid retention, so loop diuretics rarely help. Switching to a lower dose or adding an ACE inhibitor (which can counteract the arteriolar dilation-driven edema) is the standard clinical approach.

Flushing and palpitations occur in approximately 2 to 3% of patients. Dizziness is more common during initial titration. Amlodipine does not impair cardiac contractility to a clinically significant degree at therapeutic doses, making it safe in patients with preserved ejection fraction heart failure, though the 2022 AHA/ACC Heart Failure guideline notes that amlodipine has not shown mortality benefit in HFrEF and should be used cautiously.

Gingival hyperplasia is a rare but documented effect seen with long-term CCB therapy, with an estimated incidence below 2%. A PubMed review on CCB-induced gingival overgrowth identifies amlodipine as lower-risk than nifedipine within the dihydropyridine class.

Amlodipine is Pregnancy Category C (FDA old classification) and is generally avoided in pregnancy. The 2018 ACC/AHA hypertension guideline endorses labetalol, nifedipine long-acting, and methyldopa as preferred agents during pregnancy. Guideline reference at AHA Journals.

Drug Interactions: Statins Matter Here

The most clinically significant drug interaction involving amlodipine in a cardiometabolic practice is with simvastatin. Amlodipine inhibits CYP3A4 and raises simvastatin plasma concentrations by approximately 77%, increasing the risk of myopathy and rhabdomyolysis. The FDA issued a drug safety communication capping simvastatin at 20 mg/day in patients taking amlodipine. The FDA communication is here. Patients who need more aggressive LDL lowering alongside amlodipine should be switched to atorvastatin or rosuvastatin, neither of which carries this restriction.

Atorvastatin (Lipitor) is metabolized by CYP3A4, and amlodipine raises atorvastatin AUC by about 18%, a modest increase that the prescribing labels for both drugs note as clinically acceptable. No dose adjustment is required. See the atorvastatin FDA prescribing information.

Rosuvastatin (Crestor) is metabolized primarily by CYP2C9, not CYP3A4, so amlodipine produces no meaningful interaction. This makes rosuvastatin a pharmacokinetically clean choice in patients receiving amlodipine. Rosuvastatin FDA label here.

Ezetimibe (Zetia) blocks cholesterol absorption at the NPC1L1 transporter in the small intestine and has no known interaction with amlodipine. The IMPROVE-IT trial (N = 18,144) showed that adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite cardiovascular endpoint by an additional 6.4% relative risk reduction vs. simvastatin alone (HR 0.936 to 95% CI 0.89 to 0.99, P = 0.016). IMPROVE-IT is published in the New England Journal of Medicine. For a patient on amlodipine who cannot tolerate simvastatin doses above 20 mg, adding ezetimibe to low-dose simvastatin or switching to rosuvastatin plus ezetimibe is a rational path to achieving guideline LDL targets.

Cyclosporine raises amlodipine levels. Strong CYP3A4 inhibitors (clarithromycin, itraconazole, ritonavir) can raise amlodipine concentrations significantly; blood pressure monitoring should be intensified. NIH drug interaction data confirm this.

Amlodipine vs. Other Antihypertensives: When to Choose a CCB

Choosing between a CCB, an ACE inhibitor, an ARB, or a thiazide diuretic depends on patient-specific factors. The table below summarizes where amlodipine holds a clinical edge.

Amlodipine is preferred when a patient has isolated systolic hypertension (common in older adults), angina, or known peripheral arterial disease. It does not worsen insulin sensitivity, unlike high-dose thiazides and beta-blockers, making it attractive in patients with metabolic syndrome or pre-diabetes. A 2016 meta-analysis in Diabetes Care (N = 154,788) found that CCBs were associated with a lower incidence of new-onset type 2 diabetes than beta-blockers.

ACE inhibitors and ARBs are preferred over CCBs when diabetic nephropathy or heart failure with reduced ejection fraction is present. Thiazide diuretics remain preferred in Black patients per ALLHAT subgroup analysis, though combining amlodipine with a thiazide or ACE inhibitor is very common in clinical practice. ALLHAT subgroup data in JAMA.

Beta-blockers are not recommended as first-line antihypertensives without a compelling indication (angina, post-MI, heart failure) per the 2017 ACC/AHA hypertension guideline, giving amlodipine an advantage for uncomplicated hypertension. ACC/AHA guideline at AHA Journals.

Amlodipine Plus Statins: The Caduet Combination

Pfizer's fixed-dose combination product Caduet pairs amlodipine (2.5, 5, or 10 mg) with atorvastatin (10, 20, 40, or 80 mg) in a single tablet. The rationale is that many patients with hypertension also meet criteria for statin therapy. A patient with stage 1 hypertension and an LDL above 190 mg/dL, for example, needs both drugs. One tablet instead of two improves adherence.

The CAMELOT trial (N = 1,991) studied amlodipine 10 mg, enalapril 20 mg, or placebo in coronary artery disease patients with normal or near-normal blood pressure. Amlodipine reduced adverse cardiovascular events by 31% vs. placebo (P = 0.003), and the IVUS sub-study showed that amlodipine-treated patients had significantly less coronary atherosclerosis progression than placebo. CAMELOT is published in JAMA.

Combining the lipid-lowering power of atorvastatin with the BP-reducing and plaque-stabilizing effects of amlodipine represents the rationale behind Caduet. The Caduet FDA label notes that the pharmacokinetics of each component are unchanged in the fixed-dose combination.

The ASCOT-LLA sub-study enrolled 10,305 hypertensive patients already receiving amlodipine-based or atenolol-based BP therapy and randomized them to atorvastatin 10 mg vs. placebo. Atorvastatin reduced nonfatal MI and fatal CHD by 36% (HR 0.64 to 95% CI 0.50 to 0.83, P = 0.0005) on top of BP treatment, showing that adding a statin to amlodipine-based therapy magnifies cardiovascular protection beyond BP lowering alone. ASCOT-LLA is in The Lancet.

Comparing the Statins: Atorvastatin, Rosuvastatin, Simvastatin, and Ezetimibe

When a patient takes amlodipine and needs LDL reduction, three statin choices dominate clinical practice.

Atorvastatin (Lipitor, generic) is the world's best-selling statin. The TNT trial (N = 10,001) showed that atorvastatin 80 mg reduced major cardiovascular events by 22% vs. atorvastatin 10 mg (HR 0.78, P<0.001), establishing high-intensity therapy as superior to moderate-intensity therapy in established ASCVD. TNT is in the New England Journal of Medicine. As noted above, atorvastatin has a minimal and clinically acceptable interaction with amlodipine.

Rosuvastatin (Crestor, generic) produces the largest LDL reductions per milligram within the statin class. JUPITER (N = 17,802) showed that rosuvastatin 20 mg in patients with LDL below 130 mg/dL but hsCRP at or above 2 mg/L reduced the composite cardiovascular endpoint by 44% vs. placebo (HR 0.56, P<0.00001) and cut LDL by a mean 50%. JUPITER is in the New England Journal of Medicine. No dose cap exists when rosuvastatin is co-administered with amlodipine.

Simvastatin (Zocor, generic) was studied in the 4S trial (N = 4,444), which demonstrated a 30% reduction in all-cause mortality (P = 0.0003) in patients with coronary disease and elevated LDL. 4S is available via PubMed. The key limitation when paired with amlodipine is the 20 mg/day dose cap, which restricts simvastatin to moderate-intensity therapy at best in this combination. Clinicians prescribing simvastatin who then add amlodipine must reduce the simvastatin dose or switch agents.

Ezetimibe (Zetia, generic) is not a statin but is used alongside them. It lowers LDL by approximately 18 to 20% as monotherapy or when added to a statin. The SHARP trial (N = 9,270) showed that simvastatin 20 mg plus ezetimibe 10 mg reduced major atherosclerotic events by 17% vs. placebo in patients with chronic kidney disease (RR 0.83 to 95% CI 0.74 to 0.94, P = 0.0021). SHARP is in The Lancet. Because ezetimibe has no CYP3A4 interaction with amlodipine, adding it to low-dose simvastatin 20 mg (the maximum allowed with amlodipine) is a practical strategy to reach guideline LDL targets without switching statins.

The 2022 ACC Expert Consensus Decision Pathway states: "For very high-risk ASCVD patients not at LDL-C goal on maximally tolerated statin, ezetimibe should be added before PCSK9 inhibitor therapy." The ACC consensus is available through the AHA Journals. This guidance applies directly to patients on amlodipine plus a dose-capped simvastatin.

Special Populations

Elderly patients. Amlodipine's long half-life and minimal first-pass variability make it well tolerated in older adults. Starting at 2.5 mg reduces the risk of orthostatic hypotension. The ALLHAT trial enrolled patients aged 55 and older (mean age 67) and found no excess adverse events with amlodipine vs. chlorthalidone in this population. ALLHAT data in JAMA.

Patients with diabetes. Hypertension and dyslipidemia cluster with type 2 diabetes. The American Diabetes Association's 2024 Standards of Care specify an LDL target below 70 mg/dL for adults with diabetes and ASCVD, and below 100 mg/dL for those with diabetes but no ASCVD, using high-intensity statin therapy as the backbone. ADA Standards are available at Diabetes Care. Amlodipine fits well in this population because it does not impair glycemic control, whereas high-dose thiazides can raise fasting glucose.

Patients with chronic kidney disease. Amlodipine does not require dose adjustment in CKD and does not worsen renal function. It is listed as an acceptable antihypertensive in the KDIGO 2021 Blood Pressure Guideline for patients with CKD not on dialysis. KDIGO 2021 BP guideline is indexed on PubMed.

Patients with liver disease. The half-life extends beyond 60 hours in hepatic impairment, requiring a starting dose of 2.5 mg and slow up-titration. FDA prescribing information details this.

Monitoring and Follow-Up

After starting amlodipine, blood pressure should be rechecked within 2 to 4 weeks. If 10 mg daily does not achieve the target (systolic below 130 mmHg in high-risk patients per the 2017 ACC/AHA guideline), a second agent should be added rather than exceeding the maximum dose.

Liver function testing is not routinely required for amlodipine alone, unlike statins. For patients on concurrent atorvastatin or rosuvastatin, the ACC/AHA lipid guideline recommends checking a fasting lipid panel and ALT at baseline, 4 to 12 weeks after starting or titrating, and then every 3 to 12 months as clinically indicated. ACC/AHA lipid guideline at AHA Journals.

Creatine kinase (CK) should be checked if a patient on amlodipine plus simvastatin develops unexplained muscle pain, given the pharmacokinetic interaction. A CK level above 10 times the upper limit of normal with symptoms warrants statin discontinuation. The FDA's simvastatin safety communication provides specific guidance on myopathy monitoring.

Peripheral edema should be assessed at each follow-up visit. If edema is severe or functionally limiting at 10 mg, switching to an ACE inhibitor or ARB, or adding low-dose lisinopril (which can attenuate CCB-induced edema), is preferable to adding a diuretic. A PubMed review of CCB-induced edema mechanisms confirms the arteriolar dilation mechanism and the ACE-inhibitor countermeasure.

Patients with concurrent statin prescriptions should be reviewed for the simvastatin interaction at every medication reconciliation. If simvastatin 40 mg or 80 mg was prescribed before amlodipine was added, the simvastatin dose must be reduced to 20 mg or the statin must be changed. Start with a targeted review of the current simvastatin dose before the first amlodipine prescription is written.